Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30992310 | 1.00 | SIRT2 (0.38) | SIRT2SIRT1SIRT5SIRT3HTR2A | |
| SCHEMBL30781664 | 0.93 | SIRT5 (0.36) | SIRT2SIRT1SIRT5SIRT3SSTR3 | |
| SCHEMBL23880502 | 0.88 | MAP1LC3B (0.37) | SIRT5HTR2ASSTR3PTPN1 | |
| SCHEMBL19432556 | 0.88 | MAP1LC3B (0.37) | SIRT5HTR2ASSTR3PTPN1 | |
| SCHEMBL23880537 | 0.88 | MAP1LC3B (0.37) | SIRT5HTR2ASSTR3PTPN1 | |
| SCHEMBL31035944 | 0.88 | MAP1LC3B (0.37) | SIRT5HTR2ASSTR3PTPN1 | |
| SCHEMBL29423538 | 0.87 | MDM2 (0.39) | SIRT2SIRT1SIRT5SIRT3HTR2A | |
| SCHEMBL12094377 | 0.87 | HTR2A (0.40) | SIRT2SIRT1SIRT5SIRT3HTR2A | |
| SCHEMBL12944195 | 0.87 | HTR2A (0.40) | SIRT2SIRT1SIRT5SIRT3HTR2A | |
| SCHEMBL2734925 | 0.87 | HTR2A (0.40) | SIRT2SIRT1SIRT5SIRT3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-06-26 | — | — | US | disclosed |
| US-11998611-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2024-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998611-B2 | Cryptophycin antibody conjugates for the treatment of cancer | CLSPN, HCCS, INCENP | SIRT2 2704/4885SIRT1 3253/4885SIRT5 2306/4885 |
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | RPN1, CLSPN, FRG1 | SIRT2 3306/4885SIRT1 2440/4885SIRT5 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.